• Bemcentinib-Keytruda Combo Effective in Some Advanced NSCLC Patients with Poor Prognosis
  • Single-Blinded Trial Design Prevents Patients From Withdrawing Prematurely, Analysis Shows
  • FDA Grants N-803 Combo Breakthrough Therapy Status for Non-Muscle Invasive Bladder Cancer
  • Tecentriq-chemo Combo OK’d as First-line Treatment for Certain Metastatic NSCLC Patients
  • Bavencio First-line Maintenance Failed to Extend Survival in Patients with Advanced Gastric and GEJ Cancer
  • Surface Oncology Asking to Open Trial of Antibody Therapy for Advanced Solid Cancers
  • Treatment With VBI-1901 Linked to Tumor Stabilization in Recurrent Gliobastoma Patients in Phase 1/2 Trial
  • CytomX Initiates Phase 2 Trial Testing CX-072, Yervoy Combo in Relapsed or Refractory Melanoma
  • 2 Imfinzi Combos Delay Cancer Progression in Metastatic NSCLC, Interim Phase 3 Data Show
  • MDNA55 Increases Survival in Glioblastoma, Notably in Patients With High ILR4 Levels, Early Trial Data Show
  • Opdivo-Yervoy Plus Shorter Chemotherapy Course Extends Survival of Patients with Advanced Lung Cancer, Early Trial Data Show
  • Tecentriq-Avastin Prolongs Life of Patients with Advanced Liver Cancer in Trial, Roche Reports